Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
← catalyst calendarNCT03690336 · readout in 408 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
10estimated
Sites
2
Countries
Netherlands, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-10-01 | actual | When the study began enrolling |
| Primary completion | 2027-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2018-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Haemophilia B
Intervention
- Drug: Nonacog beta pegol
Primary outcome
what the primary-completion date above is the date OFAdverse Drug Reactions (ADRs) reported to the registries with suspected relation to nonacog beta pegol in patients with haemophilia B
measured From start of data collection (week 0) to end of data collection (after 9 years)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed